7Baggers
 in8bio reports improved financials amid ongoing challenges  TipRanks Fri, 07 Nov 2025 06:24:55 GMT
 IN8bio’S Losses Shrink As Analysts Rally Behind Its Stock  Finimize Fri, 07 Nov 2025 05:00:12 GMT
 IN8bio Q3 net loss narrows to $3.9 mln, R&D expenses down  TradingView Thu, 06 Nov 2025 21:25:27 GMT
 IN8Bio Reports Improved Financials Amid Ongoing Challenges  TipRanks Thu, 06 Nov 2025 08:00:00 GMT

IN8bio, Inc.
(NASDAQ:INAB) 

INAB stock logo

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I cli...

Founded: 2016
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends